| | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung C . . . |
Ongoing |
20 May 2020 |
| | A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in . . . |
Completed |
13 Feb 2020 |
| | A phase III, multicenter, observer blind, randomized, controlled study to evaluate immuneequivalence of multi-dose formulation against single-dose formulation of Vi-DT Typhoidconjugate vaccine and saf . . . |
Completed |
02 Aug 2021 |
| | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult patients with stages AJCC/UIC . . . |
Ongoing |
20 May 2021 |
| | A Phase III, Open-label, Multicentre, Randomised Trial to Establish Safety and Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients Eligible to . . . |
Terminated |
14 Apr 2020 |
| | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZ . . . |
Ongoing |
30 Nov -0001 |
| | A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutatio . . . |
Ongoing |
12 Jan 2021 |
| | A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicenter, Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage . . . |
Ongoing |
11 Mar 2021 |
| | A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing M . . . |
Ongoing |
16 Nov 2021 |
| | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma . . . |
Ongoing |
11 Mar 2021 |
| | A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy A . . . |
Ongoing |
29 Jan 2021 |
| | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab a . . . |
Ongoing |
18 May 2020 |
| | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine + Cisplatin for Neoadjuvant Treatment Followed by Dur . . . |
Ongoing |
19 May 2020 |
| | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with . . . |
Pending |
30 Nov -0001 |
| | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanc . . . |
Ongoing |
18 May 2020 |
| | A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received . . . |
Pending |
30 Nov -0001 |
| | A prospective, open-label, interventional phase IV study to assess the safety of EupentaTM Inj. {fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [r . . . |
Completed |
20 Aug 2021 |
| | A prospective, Phase I, randomized, controlled, open label study to assess the reactogenicity, safety and immunogenicity of a combined liquid DTwP-rHepB-Hib-IPV vaccine when administered to healthy ch . . . |
Completed |
02 Aug 2019 |
| | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient . . . |
Completed |
28 Dec 2021 |
| | A prospective, randomized, open-label, comparative study to assess the efficacy, safety and tolerability of aztreonam-avibactam (ATM-AVI) and best availability therapy for the treatment of serious inf . . . |
Ongoing |
31 Dec 2021 |
| | A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events |
Ongoing |
30 Nov -0001 |
| | A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) caus . . . |
Pending |
07 May 2021 |
| | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular . . . |
Pending |
21 May 2021 |
| | A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephr . . . |
Completed |
02 Mar 2020 |
| | A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis . . . |
Ongoing |
02 Mar 2020 |